Search
Mathai Mammen recaps the first clinical data Parabilis Medicines reported on its beta-catenin program earlier this month at EMSO and AACR-NCI-EORTC 2025. Plus, degraders for prostate cancer, and more.
He explains the company's "Helicon" peptide platform, and why he believes it is well suited to target previously undruggable problems like beta-catenin. Then he discusses clinical presentations on this program in multiple tumor types, and preclinical data on two degrader programs for prostate cancer.
Oct 31
Mathai Mammen provides an update on the latest at FogPharma, and his philosophy of following the cadence of science, not the calendar
The Chairman and CEO of FogPharma describes the progress the company has made this year, including on the lead β-catenin/TCF4 inhibitor...
Oct 1, 2024
Mathai Mammen on being back to company building at Fog Pharma
He describes how Fog is leveraging the way α-helices mediate interactions with other proteins to solve the undruggable problem.
Feb 28, 2024
.png){kind=logo}
